Overall Rating
Novartis (NVS)
Price*: $47.68 | Dividend: $1.47 | Dividend Yield: 3.08%
This stock has never had a high enough Dividend.com Rating to qualify for our Best Dividend Stocks list.
Dividend Stock Ratings Breakdown
Stock is stuck in an uninspiring six-month trading range.
Stock's dividend yield is adequate.
This rating is directly related to the length and consistency of a company's dividend payouts.
Dividend payouts are consistent, but increases small.
Earnings estimates are basically unchanged.
Price and Dividend Info
Recent Headlines
- Novartis Streamlines Divisions to Focus on U.S. Markets (NVS)
Mon, Oct 20, 2008 - Potential Ban on Kids Cold Remedies May Affect Pharmaceutical Sector (JNJ, WYE, NVS, PG)
Thu, Oct 2, 2008 - 28 (!) Dividend Stocks Removed from Our Recommended List
Tue, Sep 9, 2008 - Dividend Stock Recommendation Changes (NVS, SQM, MOS, CHK, FRO, CAJ, BUCY, PWE, APA, OSG, BPT, NTE)
Mon, Aug 4, 2008 - Novartis Can Relieve Investor Stress (NVS)
Mon, Aug 4, 2008
Profile & Recommendation
Company Profile
Novartis- (NVS)- provides healthcare solutions that address the needs of patients and societies worldwide. Its Pharmaceuticals division researches, develops, manufactures, distributes, and sells pharmaceuticals in therapeutic areas, including cardiovascular and metabolism; oncology and hematology; neuroscience; respiratory; infectious diseases, transplantation, and immunology; ophthalmics, dermatology, gastrointestinal, and urinary; and arthritis and bone. The company's Vaccines and Diagnostics division focuses on the development of preventive vaccine treatments and diagnostic tools. It offers meningococcal, pediatric, and travel vaccines; and blood testing and molecular diagnostics for preventing the spread of infectious diseases. Novartis' Sandoz division develops, produces, and markets drugs, as well as pharmaceutical and biotechnological active substances. Its Consumer Health division includes three units: Over-The-Counter Medicines (OTC), Animal Health, and CIBA Vision. OTC unit offers self medications; Animal Health unit provides veterinary products for farm and companion animals; and CIBA Vision unit markets contact lenses, lens care products, and ophthalmic products. Novartis has strategic alliance with Morphosys AG for the discovery and development of biopharmaceuticals. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Recommendation
Based on our rating criteria, this stock has achieved a "Neutral" rating. Stocks with a neutral rating are considered mediocre investments in terms of expected price growth and dividend payments.
Stock Notes
This large cap stock does not make an attractive dividend stock investment at this time.
Important Dividend Dates
Direct Competitors
RSS Feeds